Apyx Medical Corporation

As of June 30, 2026, Apyx Medical Corporation carries a market capitalization of 166.78M, placing it among publicly traded companies globally. Its enterprise value stands at 177.67M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Apyx Medical Corporation's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Apyx Medical Corporation has 42.12M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.25, and the price-to-book ratio stands at 17.87.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.47 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 177.67M versus a market cap of 166.78M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Apyx Medical Corporation maintains a current ratio of 5.68, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 357.35, indicating elevated leverage, while an interest coverage ratio of -0.49 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Apyx Medical Corporation posted a negative return on equity (ROE) of -96.38, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -14.48, reflecting losses generated across the asset base. The company generates approximately 244,937.24 in revenue per employee across its workforce of 208.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.25 indicates how many times Apyx Medical Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Apyx Medical Corporation recorded 384,256.70 in income tax expense. The company reported a pretax loss of -6.98M and -7.56M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Apyx Medical Corporation's stock has declined approximately 17.69% over the past 52 weeks. The 50-day moving average sits at 2.48, while the 200-day moving average is 3.15.

Over the twelve months ended June 30, 2026, Apyx Medical Corporation generated 51.13M in revenue and converted that into -7.56M in net income, yielding earnings per share of -0.18. EBITDA reached -2.41M, while operating income came in at -3.10M.

As of June 30, 2026, Apyx Medical Corporation holds 24.17M in cash and equivalents against 34.69M in total debt, resulting in a net debt position of 6.75M. Total book value stands at 9.33M, with working capital of 38.34M providing operational flexibility.

Apyx Medical Corporation produced -8.87M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -805,276.00 in capital expenditures, free cash flow totaled -9.67M - equivalent to -0.23 per share.

Over the twelve months ended June 30, 2026, Apyx Medical Corporation posted a gross margin of 63.50, reflecting its pricing power and cost economics. The operating margin of -6.06 and net profit margin of -14.78 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -5.82: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -5.04, meaning Apyx Medical Corporation raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Apyx Medical Corporation's most recent stock split took place on January 6, 1994 with a 15:1 split ratio.

As of June 30, 2026, Apyx Medical Corporation has an Altman Z-Score of 1.75, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.